ifosfamide / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

18 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ifosfamide / Generic mfg.
2014-004678-41: Etude prospective de phase II d’évaluation d’une prise en charge multimodale des métastases ganglionnaires inguinales des carcinomes épidermoïdes du pénis par lymphadénectomie bilatérale et chimiothérapie TIP (paclitaxel, ifosfamide et cisplatine).

Not yet recruiting
2
37
Europe
Concentrate for solution for infusion, Solution for infusion, PACLITAXEL, IFOSFAMIDE, CISPLATINE
UNICANCER, Institutionels
Tumeur du pénis, Tumeur du pénis, Diseases [C] - Cancer [C04]
 
 
NU 16H07, NCT03077828: Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Active, not recruiting
2
43
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Northwestern University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
Lymphocyte-Rich Classical Hodgkin Lymphoma, Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma, Recurrent Mixed Cellularity Classical Hodgkin Lymphoma, Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma, Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma, Refractory Mixed Cellularity Classical Hodgkin Lymphoma, Refractory Nodular Sclerosis Classical Hodgkin Lymphoma
12/20
12/24
2021-001085-37: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. Chimiothérapie néo-adjuvante plus retifanlimab (INCMGA00012)chez les patients porteurs de sarcomes rétropéritoneaux sélectionnés : une étude randomisée de phase II.

Not yet recruiting
2
66
Europe
Retifanlimab, DOXORUBICIN, HOLOXAN, INCMGA00012, Solution for infusion, Powder for infusion, DOXORUBICIN, HOLOXAN (Ifosfamide)
Institut Bergonié, Incyte Biosciences International Sarl
retroperitoneal sarcomas sarcomes rétropéritonéaux, retroperitoneal sarcomas sarcomes rétropéritonéaux, Diseases [C] - Cancer [C04]
 
 
LYTPET, NCT00324467: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Active, not recruiting
2
150
Canada
Cyclophosphamide, Cytoxan®, Neosar®, Doxorubicin, Adriamycin ®, Rubex®, Vincristine, Oncovin ®, Vincasar Pfs ®, Vincristine Sulfate, LCR, VCR, Prednisone, Sterapred®, Sterapred® DS, Prednisone Intensol, Ondansetron, Zofran®, Zofran® ODT, Zuplenz®, Dexamethasone, Decadron®, Dexamethasone Intensol®, Dexpak® Taperpak®, Diphenhydramine, Aler-Dryl®, Benadryl®, Nytol®, Diphenhist®, Acetaminophen, Tylenol®, Ifosfamide, Ifex®, Isophosphamide, Mesna (IV), Mesnex®, Sodium 2-mercaptoethanesulfonate, Mesna (oral), Carboplatin, CBDCA, Etoposide, Etopophos®, VP-16, Rituximab, Rituxan®, PET Scan, Positron emission tomography (PET) scan
British Columbia Cancer Agency, Hoffmann-La Roche
Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
12/21
12/21
NCT04154189 / 2019-003696-19: A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

Completed
2
81
Europe, Canada, US, RoW
Lenvatinib, E7080, Ifosfamide, Etoposide
Eisai Inc., Merck Sharp & Dohme LLC
Osteosarcoma
06/22
08/23
2023-000169-14: Clinical Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma Studio clinico su Treosulfan/Melfalan ad alte dosi come trattamento di consolidamento nel sarcoma di Ewing ad alto e altissimo rischio di nuova diagnosi

Not yet recruiting
2
60
Europe
Trecondi, Vincristina, Cyclophosphamide, Doxorubicin, Ifosfamide, Etoposide, Melphalan, Powder for solution for infusion, Solution for injection, Powder for injection, Concentrate for solution for infusion, Powder and solvent for solution for injection/infusion, TRECONDI 1 g, TRECONDI 5 g
Fondazione Santobono Pausilipon ONLUS, Medac Gesellschaft für klinische Spezialpräparate m.b.H.,
Ewing Sarcoma Sarcoma di Ewing, Ewing sarcoma, a bone tumor affecting children, adolescents and young adults Sarcoma di Ewing, un tumore osseo che colpisce bambini, adolescenti e giovani adulti, Diseases [C] - Cancer [C04]
 
 
NCT04012827: Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma

Recruiting
2
108
RoW
Apatinib Mesylate, doxorubicin, ifosfamide, Apatinib
Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd.
Soft Tissue Sarcoma
06/23
12/23
OAIE, NCT05277480: Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma

Completed
2
81
RoW
Apatinib+IE, IE
Peking University People's Hospital, Jiangsu HengRui Medicine Co., Ltd.
Effect of Drug, Drug, Toxicity
06/23
11/23
NCT03736616: Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Recruiting
2
47
US
Carboplatin, Ifosfamide, Etoposide, VP-16, Rituximab, Rituxan, Carmustine, BCNU, Cytarabine, ARA-C, Melphalan, Autologous HSCT, Autologous Hematopoeitic Stem Cell Transplantation, Acalabrutinib
Swedish Medical Center, Acerta Pharma BV
Diffuse Large B Cell Lymphoma
09/23
09/23
NCT06277154: MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Not yet recruiting
2
148
RoW
MASCT-I, Doxorubicin, Doxorubicin hydrochloride for Injection, Ifosfamide, Ifosfamide for Injection
HRYZ Biotech Co.
Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma, Undifferentiated Pleomorphic Sarcoma, Epithelioid Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Fibrosarcoma, Pleomorphic Rhabdomyosarcoma, Endometrial Stromal Sarcoma, Desmoplastic Small Round Cell Tumor
02/26
02/27
P+R-ICE, NCT05221645: Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
65
Europe
Pembrolizumab, KEYTRUDA, Rituximab, MabThera, Ifosfamide, Carboplatin, Etoposide
University of Southampton, Merck Sharp & Dohme LLC
Diffuse Large B Cell Lymphoma
10/24
12/25
TORNADO, NCT04968106: Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas

Recruiting
2
66
Europe
Doxorubicin, Ifosfamide, INCMGA00012, Retifanlimab
Institut Bergonié, Incyte Biosciences International Sàrl
Resectable Sarcoma
03/25
10/27
NCT02227199: Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Active, not recruiting
1/2
45
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis
University of Washington, National Cancer Institute (NCI), Seagen Inc.
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
03/20
09/25
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
TOUCH, NCT04425070: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma

Hourglass Dec 2022 - Dec 2022 : First-patient-in of ARM-C of TOUCH trial in combination with tislelizumab for r/r/ peripheral T- and NK/T-cell lymphoma
Checkmark Data from TOUCH trial for r/r peripheral T- and NK/T-cell lymphoma
Nov 2022 - Nov 2022: Data from TOUCH trial for r/r peripheral T- and NK/T-cell lymphoma
Checkmark Presentation of data from TOUCH trial for the treatment of NK - Cell lymphoma at ASH 2021
Dec 2021 - Dec 2021: Presentation of data from TOUCH trial for the treatment of NK - Cell lymphoma at ASH 2021
Active, not recruiting
1/2
56
RoW
ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab
Antengene Corporation
Peripheral T-cell Lymphoma, NK/T-cell Lymphoma
12/24
12/24
NCT05813327: Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Recruiting
1/2
35
US
ADI PEG20, PEGylated arginine deiminase, Ifosfamide, ifex, Radiotherapy, Mesna, sodium 2-mercaptoethane sulfonate
Washington University School of Medicine, Polaris Group
Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
01/26
01/28
iMATRIX GLO, NCT05533775 / 2021-006326-48: A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
65
Europe, US, RoW
Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin, Etoposide, Tocilizumab
Hoffmann-La Roche
Mature B-Cell Non-Hodgkin Lymphoma
10/27
10/27
EPCORE NHL-2, NCT04663347 / 2020-000845-15: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Checkmark Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Checkmark Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Checkmark Data from arm-4 of EPCORE NHL-2 trial for r/r DLBCL at ASH 2022
More
Recruiting
1/2
662
Europe, US, RoW
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, rituximab and lenalidomide, R2, rituximab and bendamustine, BR, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, R-DHAX/C, gemcitabine and oxaliplatin, GemOx, Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, R mini-CHOP, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate, R-ICE
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
03/29
03/29

Download Options